Current stock page

Catalysts

GMAB Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

GMABGenmab A/S

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$51.37−$0.37 (−0.72%)

Latest quote

  • Momentum
    94
  • Value
    71
  • Quality
    72
  • Risk resilience
    58
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 16, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 77/100

Momentum 94/100 and sentiment — before the next covered event.

Recent coverage
4 articles

Updated Nov 15, 2026 · Sentiment -11.02%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 94/100AIQ Edge 10/10 Sector Leader
Beat rate
75%
6 of 8 reported periods
Average surprise
+17.2%
Across covered historical reports
Latest result
+55.6%
Nov 5, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 5, 2026—$0.36$0.56+55.6%$1.2B$1.19B
Aug 6, 2026—$0.37$0.54+45.9%$1.12B$1.16B
May 7, 2026—$0.15$0.09-42.0%$905.77M$896M
Feb 17, 2026—$0.46$0.05-89.1%$1.07B$1.06B
Nov 6, 2025—$0.48$0.65+35.4%$1.01B$1.02B
Aug 7, 2025—$0.39$0.54+38.5%$952.56M$924.81M
May 8, 2025—$0.23$0.31+34.8%$755.47M$725.99M
Feb 12, 2025—$0.36$0.57+58.3%$894.71M$895.8M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
11
Buy
2
Hold
12-month analyst target
$55.50
+8.04% versus current price
Based on 13 analyst observations. Targets are estimates, not predictions.
Low target
$42.00
-18.24% vs latest price
Average target
$55.50
+8.04% vs latest price
High target
$70.00
+36.27% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 16, 2027

Next known earnings or reporting date.

EPS estimate$0.23

Current analyst expectation for the upcoming report.

Revenue estimate$1.25B

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score94

Where event reaction would show up first.

AIQ score77/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
13
Average target
$55.50
Target upside
8.04%
Target range
$42.00 - $70.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
1
Neutral
2
Negative
1
gurufocus.com · Oct 28, 2026

Genmab (GMAB) Shares Rally 15% on Positive Phase 3 Trial Results for Head and Neck Cancer

On October 28, 2026, Genmab (ticker: GMAB) saw its ADR shares surge nearly 15% following the announcement of compelling Phase 3 trial data from its LiGeR-HN1 st

gurufocus.com · Oct 26, 2026

GMAB Upgraded by JP Morgan -- Rating Raised to Overweight

On October 7, 2026, Genmab (GMAB) received an upgrade from JP Morgan, with analyst James Gordon changing the rating from Neutral to Overweight. This marks a pos

gurufocus.com · Oct 5, 2026

GMAB Maintained by Guggenheim -- Price Target Raised to $54.00

Genmab (GMAB) Analyst Rating Update - October 5, 2026 On October 5, 2026, Genmab (GMAB) received an updated 'Buy' rating from Guggenheim, with a new price ta

seekingalpha.com · Sep 22, 2026

Genmab A/S (GMAB) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Genmab A/S (GMAB) Bank of America Global Healthcare Conference 2026 September 22, 2026 5:55 AM EDTCompany ParticipantsAndrew Carlsen - VP & Head of...

Open full news and sentiment

GMAB Catalysts FAQ

What are the next catalysts for GMAB stock?

GMAB's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move GMAB stock?

Upcoming events that could move GMAB include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could GMAB's next earnings report affect the stock?

GMAB's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive GMAB stock higher?

GMAB could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt GMAB stock?

GMAB could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.